LQDALiquidia Corporation
Price
+84%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growth steady, the market undecided.
We are a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases such as pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC, formerly known as RareGen.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Liquidia Corporation (LQDA) reported revenue of $172M in Q2 2026 (quarter ended Jun 30, 2026), up 1843% from the same quarter a year earlier. That came with net income of $75M (44% of revenue). For the full year FY2025, revenue was $158M (+1031% year on year) and net income −$69M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 14, 2026Settlement Agreement On October 13, 2026 (the “Effective Date”), Liquidia Technologies, Inc., a Delaware corporation (the “Company”), a wholly-owned subsidiary of Liquidia Corporation, and United Therapeutics Corporation (“UTC”) entered into a settlement agreement (the “Settlement Agreement”) regarding all ongoing …Material agreement entered · Form 8-K
- Sep 30, 2026On September 30, 2026, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release regarding the litigation filed by United Therapeutics Corporation in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 and the Company’s lead …Other event · Form 8-K
- Sep 3, 2026On September 3, 2026, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to YUTREPIA ® (treprostinil) inhalation powder for the treatment of Raynaud’s phenomenon associated with systemic sclerosis.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry